巨力索具(002342.SZ):擬對河南子公司增資6000萬元
格隆匯4月8日丨巨力索具(002342.SZ)公佈,公司於2024年1月15日召開的第七屆董事會第十九次會議審議通過了《關於年產5萬噸粗直徑高端鋼絲繩及配套索具的議案》,同意巨力索具(河南)有限公司(簡稱“河南子公司”)總投資35,682.70萬元建設“年產5萬噸粗直徑高端鋼絲繩及配套索具項目”。
為便於河南子公司更快更好的完成項目建設並順利投產,對外開展和擴大業務。公司擬以自有資金人民幣6,000萬元對河南子公司進行增資。本次增資完成後,河南子公司的註冊資本由22,000萬元增加到28,000萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.